Revance Therapeutics reported $6.92M in Interest Expense on Debt for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Interest Expense On Debt Change
ALKERMES ALKS:US USD 3.55M 1.18M
Bristol Myers Squibb BMY:US USD 299M 14M
Eli Lilly And LLY:US USD 81.5M 300K
Endo International Ordinary Shares ENDP:US USD 74.93M 65M
JAZZ PHA JAZZ:US USD 83.74M 19.86M
Merk MRK:US USD 244M 4M
Neurocrine Biosciences NBIX:US USD 1.2M 1000K
Pacira Pharmaceuticals PCRX:US USD 9.86M 1.02M
Procter & Gamble PG:US USD 171M 48M
Revance Therapeutics RVNC:US USD 6.92M 3.04M
Teva Pharmaceutical Industries TEVA:US USD 230M 5M